부산대학교 도서관

Background Cardiovascular events have been reported to occur in one in five patients receiving chimeric antigen receptor T- cell (CAR-T) therapy. Commonly reported effects including cardiomyopathy, heart failure, myocardial infarction (MI), and arrhythmia. Here, we present a novel case of a patient who developed acute ST segment elevations during CAR-T cell infusion. Case summary A 76-year-old man with diffuse large B cell lymphoma was admitted for an investigational CD-19 directed, autologous CAR-T cell therapy. Less than 5 min into the CAR-T cell infusion, he developed severe chest pain, dyspnea, flushing, hypotension, and tachycardia. Electrocardiogram (EKG) showed inferior ST elevations and reciprocal lateral ST depressions. Emergent coronary angiography revealed mild non-obstructive coronary disease. ST segment changes and patient symptoms resolved after catheterization. Discussion Given the complete resolution of symptoms and EKG abnormalities in the context of non-obstructive coronary artery disease, this clinical presentation was thought to be most consistent with ST elevation MI due to coronary vasospasm. The mechanism of this vasospasm is as yet not understood and may be related to an anaphylactic reaction or a cardiotoxicity related to the cell therapy agent. As the use of CAR-T therapy continues to expand, there is a need to further characterize the full spectrum of its cardiotoxic effects. Keywords Acute coronary syndrome * Ischemia * Coronary vasospasm * Cardiooncology * Case report ESC curriculum 3.2 Acute coronary syndrome * 6.9 Cardiac dysfunction in oncology patients
Introduction Chimeric antigen receptor T-cell (CAR-T) therapy targeting CD-19 is the first Food and Drug Administration approved cell-based gene therapy. CAR-T are genetically engineered autologous or allogeneic T-cells that stably [...]